Stay updated on SubQ Efgartigimod in CIDP Clinical Trial
Sign up to get notified when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.

Latest updates to the SubQ Efgartigimod in CIDP Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdd: new operating-status notice and a new version tag v3.2.0. Delete: removal of a specific resource entry (Chronic inflammatory demyelinating polyradiculoneuropathy) and an older version tag v3.0.2. Overall, the page now signals current status and a more recent release, with a different resource mention.SummaryDifference2%
- Check22 days agoChange DetectedRemoved four MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs); overall breadth of content is reduced.SummaryDifference0.2%
- Check29 days agoChange DetectedNo substantive changes detected; only the removal of a 'Back to Top' link. The core content and other critical information remain unchanged.SummaryDifference0.1%
- Check37 days agoChange DetectedVersion updated to v3.0.2 with a Back to Top link added. The legacy v3.0.0-post.1 tag was removed.SummaryDifference0.1%
- Check44 days agoChange DetectedThe web page has been updated to a new version, specifically from v3.0.0 to v3.0.0-post.1-g752effb-HEAD.SummaryDifference0.0%
- Check51 days agoChange DetectedThe web page has undergone significant updates, including the addition of a new facility name and location details, as well as a comprehensive list of publications related to chronic inflammatory demyelinating polyradiculoneuropathy. Additionally, several outdated location entries have been removed.SummaryDifference10%
Stay in the know with updates to SubQ Efgartigimod in CIDP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.